PDA Week 2026 Showcased AI, Knowledge Management, and Proactive Quality Culture
PDA Week 2026 in Denver highlighted the rapid transition of artificial intelligence from concept to operational use across bio‑pharma quality and manufacturing. Attendees showcased AI‑driven tools for predictive risk, smart supply chains, and real‑time decision support. Sessions also borrowed NASA’s knowledge‑management practices to preserve critical expertise. Co‑chairs Kate Malachowski (Novavax) and Malav Parikh (Takeda) framed the event as a catalyst for a proactive, data‑centric quality culture.
Subcutaneous Tepezza Demonstrates Phase III Efficacy in Thyroid Eye Disease
Amgen reported that its subcutaneous formulation of teprotumumab‑trbw (Tepezza) met the primary endpoint in a phase III trial for moderate‑to‑severe active thyroid eye disease, with 76.7% of patients achieving a ≥2 mm proptosis reduction versus 19.6% on placebo. The study also showed...
Navigating the Frontiers of Advanced Therapeutics and Operational Excellence
In 2026 the biopharma sector is juggling rapid advances in emerging modalities—viral vectors, multispecific antibodies and nucleic‑acid therapies—with heightened operational discipline. Companies are deploying patient‑derived xenograft models, 3‑D organoids and AI‑enhanced spectral flow cytometry to de‑risk next‑gen immunotherapies. Manufacturing focus...
Gilead Buys Tubulis to Boost ADC Platform
Gilead Sciences announced a definitive agreement to acquire Germany‑based Tubulis for up to $5 billion, adding a clinical‑stage antibody‑drug conjugate (ADC) pipeline and a next‑generation linker‑payload platform. The deal brings Tubulis’ lead candidate TUB‑040, a NaPi2b‑targeting ADC in phase 1b/2 for platinum‑resistant...
Development of Emerging Modalities: Challenges and Strategies
The article outlines that emerging therapeutic modalities—such as antibody‑drug conjugates, multispecific antibodies, viral vectors, gene‑editing and RNA‑based medicines—present far greater molecular and manufacturing complexity than traditional biologics. Four primary hurdles are identified: structural heterogeneity, absence of universal platform processes, difficulty...
Tech Transfer Powered by Dual Site Precision
Rentschler BioPharma uses a coordinated dual‑site manufacturing model to streamline tech transfers from development to GMP production. By aligning timelines early, defining critical parameters, and managing equipment differences, the company accelerates transfer schedules while preserving product quality. The approach leverages...
From Low Yields to High Efficiency: Modernizing Complex Biologics Manufacturing
WuXi Biologics hosted a webcast detailing an integrated platform that can boost yields of complex biologics up to six‑fold while cutting manufacturing costs by as much as 80%. The approach combines platform‑based media optimization, cell‑culture intensification via WuXiUI™, downstream capacity...
From PC to CPV: Preserving Process Knowledge Through Late‑Phase Tech Transfer
Catalent’s Danielle Wittenwyler, PhD, will host a webinar on preserving years of process characterization (PC) during late‑phase tech transfers. She outlines a structured, risk‑based methodology that translates sponsor‑generated PC into Catalent’s Madison facility while maintaining design‑space intent. The approach identifies...
World Health Day FAQ: How Global Science Is Having Clinical Impact
World Health Day 2026 spotlights a wave of global partnerships that are turning research breakthroughs into everyday clinical care. AI‑driven bioinformatics platforms from MD Anderson and SOPHiA Genetics are converting complex genomics into bedside decision tools, while collaborations such as...
Analytics that Matter- How LC and MALS Drive Biosimilar Success
The FDA released draft guidance in October 2025 that reshapes biosimilar development by emphasizing analytical data. The guidance suggests that robust analytical comparability can replace or reduce comparative efficacy studies. It calls for comprehensive analytical packages using orthogonal techniques such as...
Key Considerations for Drug Development Pipelines in Early Phase Clinical Trials
Early‑phase clinical trials are shifting from traditional maximum‑tolerated dose (MTD) hunting to identifying an optimal biological dose (OBD) that balances safety, efficacy, and exposure. The FDA’s Project Optimus and related guidance now require dose‑optimization using all clinical data, prompting broader...
Teva Intensifies Biosimilar Competition with FDA Approval and Dual Filing Acceptance in US and Europe
Teva Pharmaceutical Industries received U.S. FDA approval for its denosumab‑adet biosimilar, covering all approved indications of Amgen’s Prolia, including osteoporosis and bone loss in cancer patients. The company also secured simultaneous acceptance of regulatory filings with the FDA and the...
The BioPharm Brief: Talking Lifecycle Optimization, Strategic Investment, and Collaboration Shaping Growth Trajectory
The FDA has approved a higher-dose regimen of nusinersen (Spinraza) for spinal muscular atrophy, aiming to boost drug exposure and improve long‑term motor function. The approval underscores a broader industry shift toward lifecycle optimization of RNA‑targeted therapies. Simultaneously, biopharma firms...
Examining the Architecture of Next-Gen Biotherapeutic Modalities
BioPharm Drug Digest will host a free webinar on April 17, 2026, exploring how the biopharma sector is redesigning antibodies, RNA therapies, and cell therapies with multifunctional architectures. The session highlights programmable biology, next‑generation delivery platforms, and digitized biology models...
Drug Digest: Examining the Growing Role of Partnerships in Modern Bioprocessing and Biopharma R&D with Bristol Myers Squibb's Dr. Manisha...
In a debut interview for BioPharm Drug Digest, Bristol Myers Squibb’s senior vice‑president of Product Development, Manisha P. Desai, explains how strategic, end‑to‑end partnerships are reshaping bioprocessing and biopharma R&D. She highlights a shift from traditional fee‑for‑service outsourcing to deep collaborations that integrate...
Market Shifts Powering the Growth of Sterile Injectable Manufacturing
The sterile injectable contract manufacturing market is rapidly evolving as demand surges for both large‑scale biologics and niche, small‑batch therapies. Leading CDMOs are responding by expanding production capacity, building global redundancy, and investing heavily in specialized talent. Development and pre‑commercial...
Earendil Labs to Scale AI-Driven Biologics Platform with $787 Million Funding
Earendil Labs announced a $787 million financing round, the largest recent capital raise for AI‑enabled drug development. The funding, led by Sanofi and the Biotech Development Fund, will be used to scale its AI‑driven biologics discovery platform, expand R&D teams, and...
Sun Pharma's Tildrakizumab Advances Into Psoriatic Arthritis as FDA Accepts sBLA
Sun Pharmaceutical's tildrakizumab (Ilumya) received FDA acceptance for a supplemental biologics license application to treat active psoriatic arthritis. The sBLA is backed by two Phase III INSPIRE studies involving more than 800 patients, which met primary endpoints with significant ACR20 improvements...
Shilpa Biologicals, mAbTree Program Targets Immune Pathway in Rare Blood Cancers
Shilpa Biologicals and mAbTree Biologics received FDA orphan drug designation for an investigational monoclonal antibody that targets an immune‑evasion pathway in essential thrombocythemia and polycythemia vera. The designation validates the novel mechanism and accelerates plans for IND‑enabling studies and first‑in‑human...
Beyond the Safety Check: Why First-in-Human Trials Demand a New Approach in 2026
Phase I trials have evolved from simple safety checks into data‑rich, adaptive studies that integrate biomarker strategies, exposure‑response analyses, and formulation optimization. Regulators now expect sponsors to justify Phase II dosing decisions, making early pharmacodynamic and target‑engagement data essential. Emerging biotechs face...
Propanc Advances PRP Toward Clinical Trials for Pancreatic Cancer
Propanc Biopharma announced that its proenzyme therapy PRP is moving toward a Phase Ib first‑in‑human study for advanced pancreatic cancer. The company highlighted preclinical data showing more than 85 % tumor‑growth inhibition and secured FDA orphan‑drug designation. A validated pharmacokinetic assay developed...
Biogen Phase Ib Data Positions Salanersen for SMA Treatment Sequencing
Biogen reported Phase Ib data for its antisense oligonucleotide salanersen, showing substantial neurofilament light chain reductions and new motor milestones in children with spinal muscular atrophy (SMA) who had previously received onasemnogene abeparvovec. The study of 24 participants demonstrated a roughly...
Phase III Data Support Johnson & Johson’s Teclistamab as Second-Line Therapy for RRMM
Johnson & Johnson has filed a Type II variation with the European Medicines Agency to add teclistamab, a bispecific T‑cell‑redirecting antibody, as a second‑line monotherapy for relapsed/refractory multiple myeloma. The Phase III MajesTEC‑9 trial, enrolling 614 patients, demonstrated a 71 % reduction in...
BioNTech Co-Founders Launch New mRNA Company
BioNTech announced it will create an independent biotech company dedicated to next‑generation mRNA technologies. The spin‑out will be led by co‑founders Ugur Sahin and Özlem Türeci, who will assume management by the end of 2026. BioNTech will contribute core mRNA assets in...